Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aurora
- Development stage
- Preclinical
- Lead developer
- State Research Center of Virology and Biotechnology Vector
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Aurora is a COVID-19 vaccine candidate developed by the Vector Institute (State Research Center of Virology and Biotechnology) in Russia. In July 2021, the Swedish biotechnology company ZandCell announced its role as a manufacturing and supply partner for the vaccine, offering a production capacity of 750 million doses to facilitate global distribution, particularly in Asia, South America, and Africa. While the vaccine is intended to provide immunity against the SARS-CoV-2 virus, specific technical details regarding its technological platform, active ingredients, and precise mechanism of action have not been publicly disclosed in the available documentation. ZandCell's involvement is primarily focused on manufacturing and supply logistics rather than the primary development or sponsorship of the vaccine candidate.
- Brand names
- Aurora
- Other names
- Aurora COVID-19 vaccineAurora-CoV
02
Targets
AURKB (Aurora kinase B)AURKA (Aurora kinase A)
Beyond the preview
Go deeper on Aurora.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aurora.